DOCSLIB.ORG

Malta Medicines List April 08

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Malta Medicines List April 08 Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal 5g A07BA01 OTC Biocarbon® 0.25g Tablet Antiflatulent Dentinox® Infant Colic 42mg/ml Oral suspension Drops Antifoaming agent - Activated Dimethicone Aero-OM® 100mg/ml Oral drops emulsion Refer to PIL Preparation for colic A02X OTC or wind pain Aero-OM® 40mg Tablet Activated dimeticone, Antacid and Asilone Antacid Tablets 270mg 500mg Tablet Refer to PIL A02AB10 OTC Dried aluminium hydroxide Antiflatulent Cream Retinoid - Antiacne Adapalene Differine® 0.1% w/w Refer to PIL D10AD03 PoM preparation Gel Cardiac Preparation Adenosine Adenocor® 3mg/ml Solution for injection 15mg for Supraventricular C01EB10 PoM Arrhythmias Bisphosphonate - Alendronic Acid Agent affecting Bone Alendronic Acid 70mg Tablet 10mg M05BA04 PoM Fosamax® Once Weekly Structure and 70mg Mineralization One-Alpha® 1mcg 1mcg Capsule Alfacalcidol 1mcg Vitamin D Analogue A11CC03 PoM One-Alpha® 0.25mcg 0.25mcg Capsule soft Film-coated sustained release Xatral® SR 5mg Alpha- tablet Adrenoreceptor Alfuzosin Hydrochloride 7.5mg Antagonist - Medicine G04CA01 PoM used in Benign Xatral® XL 10mg Prolonged release tablet Prostatic Hypertrophy Alginic acid, 50mg Compound Alginate Sodium bicarbonate, 170mg Gaviscon Tablets Chewable tablets Refer to PIL Preparation - Antacid A02AX OTC Aluminium hydroxide, 100mg Preparation Magnesium trisilicate 25mg Allergan Extract of Grass Grazax® 75 000 SQ-T 75000 SQ-T Oral lyophilisate Refer to PIL Allergen Extract V01AA02 PoM Pollen from Timothy Allopurinol Zyloric® 100mg Alopron 100 Xanthine Oxidase Cellidrin® 100mg Allopurinol Tablet 400mgInhibitor - Antigout M04AA01 PoM Alopron 300 Preparation Allopurinol 300mg Zyloric® Cellidrin® 300mg Zolaram 0.5 0.5g Zolaram 1 1mg Xanax® Tablets 250 Benzodiazepine Alprazolam 250mcg Tablet 1mg N05BA12 PoM micrograms Derivative - Anxiolytic Xanax® Tablets 500 500mcg micrograms Antihidrotic - Aluminium Chloride Preparation Driclor® 20.000% Solution for topical application Refer to PIL D11AA OTC Hexahydrate Suppressing Perspiration Aluminium hydroxide, 220mg/5ml Antacid and Magnesium hydroxide, Actonorm Gel 200mg/5ml Oral suspension Refer to PIL A02AX OTC Antiflatulent Activated dimethicone 25mg/5ml Aluminium oxide, 114mg/5ml Antacid and Magnesium hydroxide, Maalox® Plus® 200mg/5ml Oral suspension Refer to PIL A02AF01 OTC Antiflatulent Simethicone 25mg/5ml Alteplase Actilyse® 50mg Pdr & solv for soln for inj or inf 0.1g Antithrombotic agent B01AD02 PoM PK-Merz® 100mg Film-coated tablets 200mg Dopaminergic Agent - Amantadine Sulphate Medicine used in N04BB01 PoM PK-Merz® Infusion 200mg/500ml Solution for infusion Refer to PIL Parkinsonism Muciclar 75mg Modified release capsule hard PoM Ambrolitic® 30mg Capsule Ambroxol Hydrochloride Mucosolvan® 30mg Tablet Mucolytic - Cough (Cyclohexanol 120mg R05CB06 Mucobroxol Syrup 15mg/5ml Preparation OTC Hydrochloride) Mucosolvan® 5mg/mL PoM Syrup Muciclar 3mg/ml OTC Aminoglycoside- Amikacin 500mg Uzix 500mg Solution for injection 1g J01GB06 PoM Antibiotic Potassium- Sparing Amiloride Hydrochloride Amiloride 5mg Tablet 10mg C03DB01 PoM Agent - Diuretic Potassium- Sparing Amiloride hydrochloride, 5mg Milorex Tablets Tablet Refer to PIL Agent + Thiazide - C03EA01 PoM Hydrochlorothiazide 50mg Diuretic Xanthine - Aminophylline Aminophylline 23.973mg/ml Solution for injection 600mg R03DA05 PoM Bronchodilator Cordarone® Scored tablet Amiodarone® 200mg Tablet Amiodarone Hydrochloride Cardilor 200 200mg Antiarrhythmic C01BD01 PoM Cordarone® 150mg Solution for injection Solian® 200 100mg Benzamide - Amisulpride Tablet 400mg N05AL05 PoM Solian® 400 400mg Antipsychotic Amirol 10 Film-coated tablets 10mg Non-selective Tryptizol 10mg Tablets Monoamine Reuptake Amitriptyline Hydrochloride 75mg N06AA09 PoM Inhibitor - Antidepressant Amirol 25 Film-coated tablets 25mg Tryptizol 25mg Tablets Amlo Amlodipine 10mg Tablets 10mg LofralTM-10 Istin™ Dihydropyridine Amlodipine Tablet 5mg derivative - Calcium C08CA01 PoM Amlo Channel Blocker Amlodipine 5mg Tablets 5mg 5mg LofralTM-5 Istin™ Ammonium chloride, 100mg/5ml Sodium citrate, 50mg/5ml Menthol, 7.75mg/5ml Menthodex Cough Expectorant - Cough Liquid extract of horehound, 0.0015ml/5ml Oral solution Refer to PIL R05X OTC Mixture Preparation Tolu tincture, 0.001ml/5ml Squill tincture, 0.001ml/5ml Liquid extract of Tussilago 0.0004ml/5ml Antifungal for topical Amorolfine Loceryl® Nail Lacquer 5%w/v Cutaneous soltuion Refer to PIL D01AE16 PoM use Augmentin®-Duo 400-57 400mg/5ml; Powder for oral suspension 57mg/5ml Noprilam DT 400 Noprilam DT Tablet Moxiclav® 875mg 125mg Film-coated tablets Augmentin 875-125mg Tablets Augmentin 250-125mg Tablets Co-Amoxiclav Tablets BP 250-125mg 250mg 125 125mg Clavomid 375 1g (Amoxicillin) Film-coated tablets Moxiclav® 375 Broad-Spectrum Amoxicilin; Augmentin Duo 500- Penicillin + Beta- J01CR02 PoM Clavulanic Acid 125mg Tablets Lactamase Inhibitor - 500mg Antibiotics 125mg Fungentin® Moxiclav® 625 500mg Noprilam Tablet 125mg Fungentin® 125mg/5ml Moxiclav® 156.25mg- 31.25mg/5ml 5ml Powder for oral suspension Fungentin® 250mg/5ml Moxiclav® Forte 62.5mg/5ml 312.5mg-5ml Augmentin® Intravenous 500mg 600mg 100mg Powder for solution for injection or 3g (Amoxicillin) infusion Augmentin® Intravenous 1000mg 1.2g 200mg Pamocil® 1000mg Tablet Moxilen Amoxil® Capsules 500mg Capsule 500mg Flemoxin Solutab® 500 500mg Tablet Amoxapen Coated tablets Moxilen Amoxil® Capsules Capsule 250mg 250mg g Amoxicillin Capsules Flemoxin Solutab® 250 Tablet Amoxicillin Sachets SF 3g Oral powder Amoxil Sachts Broad-Spectrum Amoxicillin J01CA04 PoM Penicillin - Antibiotic Amoxil Sterile powder for reconstitution 1g 500mg Moxilen Powder for solution for injection Flemoxin® Suspension 150mg/5ml Flemoxin® Drops 100mg/ml Moxilen Amoxil® Syrup Sucrose- Free Dye-Free 125mg/5ml Suspension 125mg per Powder for oral suspension 5ml Amoxil® Syrup Sucrose- Free Dye-Free Suspension 250mg per 5ml 250mg/5ml Flemoxin® Suspension Forte Amphotericin (Liposomal Polyene Antifungal AmBisone® for Injection 50mg Powder for solution for infusion 35mg J02AA01 PoM Amphotericin) Antifungal Anti-infective and Amphotericin Fungilin 10mg Lozenge 40mg antiseptic for local and A01AB04 PoM oral treatment Concentrate for solution for Amsacrine Amsidine 50mg/ml Refer to PIL Antineoplastic Agent L01XX01 PoM infusion Amylmetacresol, Strepsils® Menthol & 0.6mg 1.2mg Antiseptics + 2,4-Dichlorobenzylalcohol, Lozenge Refer to PIL R02A OTC Eucalyptus 8mg Anaesthetic Levomenthol Amylmetacresol, Strepsils® with Vitamin 0.6mg 1.2mg 2,4-Dichlorobenzylalcohol, Lozenge Refer to PIL Antiseptics R02AA20 OTC C 100mg 100mg Vitamin C Strepsils® Original Amylmetacresol; 0.6mg Strepsils® Honey & Lozenge Refer to PIL Antiseptics R02AA20 OTC 2.4-Dichlorobenzyl Alcohol Lemon 1.2mg Strepsils® Sugar Free Hormone Antagonist - Anastrozole Arimidex® 1mg Coated tablets 1mg L02BG03 PoM Antineoplastic Agent Anhydrous Glucose Dextrose 5percent 50mg Anhydrous glucose or Glucose Intravenous 50%w/v or Solution for infusion Refer to PIL Fluid replacement V06DC01 PoM Glucose Monohydrate Infusion BP 50%w/v 55%w/v 1.36% w/v Dianeal PD1 Glucose 0.57% w/v 1.36%w-v 13.6mg-ml 0.39% w/v 0.0257% w/v 0.0152% w/v 2.27% w/v Dianeal PD1 Glucose 0.57% w/v 2.27%w-v 22.7mg-ml 0.39% w/v 0.0257% w/v 0.0152% w/v 3.86% w/v Dianeal PD1 Glucose 0.57% w/v Anhydrous glucose, 3.86%w-v 38.6 mg-ml 0.39% w/v 0.0257% Sodium chloride, w/v 0.0152% w/v Solution for Peritoneal Sodium lactate, Solution for peritoneal dialysis Refer to PIL B05DB PoM Dialysis Calcium chloride, 2.27% w/v 0.538% Magnesium chloride Dianeal PD4 Glucose w/v 0.448% w/v 2.27%w-v 22.7mg-ml 0.184%w/v 0.0051% w/v 1.36% w/v 0.538% Dianeal PD4 Glucose w/v 0.448% w/v 1.36%w-v 13.6mg-ml 0.184%w/v 0.0051% w/v 3.86% w/v 0.538% Dianeal PD4 Glucose w/v 0.448% w/v 3.86%w-v 38.6 mg-ml 0.184%w/v 0.0051% w/v Anhydrous lanolin, 1% w/w 14.5% White soft paraffin, E45 w/w 12.6% Cream Refer to PIL Emollient D02AC OTC Light liquid paraffin w/w Anhydrous Lidocaine 20mg Hydrochloride; Lignospan Special Solution for Injection Refer to PIL Local
Load more

Recommended publications
  • Antiseptics and Disinfectants for the Treatment Of
    Verstraelen et al. BMC Infectious Diseases 2012, 12:148 http://www.biomedcentral.com/1471-2334/12/148 RESEARCH ARTICLE Open Access Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review Hans Verstraelen1*, Rita Verhelst2, Kristien Roelens1 and Marleen Temmerman1,2 Abstract Background: The study objective was to assess the available data on efficacy and tolerability of antiseptics and disinfectants in treating bacterial vaginosis (BV). Methods: A systematic search was conducted by consulting PubMed (1966-2010), CINAHL (1982-2010), IPA (1970- 2010), and the Cochrane CENTRAL databases. Clinical trials were searched for by the generic names of all antiseptics and disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A. Clinical trials were considered eligible if the efficacy of antiseptics and disinfectants in the treatment of BV was assessed in comparison to placebo or standard antibiotic treatment with metronidazole or clindamycin and if diagnosis of BV relied on standard criteria such as Amsel’s and Nugent’s criteria. Results: A total of 262 articles were found, of which 15 reports on clinical trials were assessed. Of these, four randomised controlled trials (RCTs) were withheld from analysis. Reasons for exclusion were primarily the lack of standard criteria to diagnose BV or to assess cure, and control treatment not involving placebo or standard antibiotic treatment. Risk of bias for the included studies was assessed with the Cochrane Collaboration’s tool for assessing risk of bias. Three studies showed non-inferiority of chlorhexidine and polyhexamethylene biguanide compared to metronidazole or clindamycin. One RCT found that a single vaginal douche with hydrogen peroxide was slightly, though significantly less effective than a single oral dose of metronidazole.
    [Show full text]
  • Adansonia Digitata L
    Veterinary World, EISSN: 2231-0916 RESEARCH ARTICLE Available at www.veterinaryworld.org/Vol.7/July-2014/10.pdf Open Access Antidiarrhoeal effect of the crude methanol extract of the dried fruit of Adansonia digitata L. (Malvaceae) Mohammed Musa Suleiman1111 , Mohammed Mamman , Ibrahim Hassan , Shamsu Garba , Mohammed Umaru Kawu21 and Patricia Ishaku Kobo 1. Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Ahmadu Bello University, Zaria, Nigeria; 2. Department of Physiology, Faculty of Veterinary Medicine, Ahmadu Bello University, Zaria, Nigeria. Corresponding author: Mohammed Musa Suleiman, email:[email protected] MM: [email protected], IH: [email protected], SG: [email protected], MUK: [email protected], PIK: [email protected] Received:06-04-2014, Revised: 12-06-2014, Accepted: 14-06-2014, Published online: 19-07-2014 doi: 10.14202/vetworld.2014.495-500 How to cite this article: Suleiman MM, Mamman M, Hassan I, Garba S, Kawu MUand Kobo PI (2014) Antidiarrhoeal effect of the crude methanol extract of the dried fruit ofAdansonia digitata L. (Malvaceae), Veterinary World 7(7): 495-500. Abstract Aim: The study was designed to evaluate the antidiarrhoeal property of the methanol extract of the fruit of Adansonia digitata using laboratory animal models. Materials and Methods : The acute oral toxicity (LD50 ) of the extract was determined in mice, while the antidiarrhoeal effect of different doses of the extract was evaluated in both mice and rats. The effect of the extract at doses of 300, 700 and 1000 mg/kg were tested against intestinal transit time, magnesium sulphate-induced gastrointestinal motility test and castor oil- induced diarrhoea in mice.
    [Show full text]
  • Topical Budesonide for Treating Giant Rectal Pseudopolyposis
    ANTICANCER RESEARCH 25: 2961-2964 (2005) Topical Budesonide for Treating Giant Rectal Pseudopolyposis CHARALAMPOS PILICHOS1, ATHENA PREZA1, MARIA DEMONAKOU2, DIMITRIOS KAPATSORIS1 and CONSTANTINOS BOURAS1 1First Department of Internal Medicine and 2Department of Pathology, Sismanogleion Hospital, Athens, Greece Abstract. Pseudopolyps are a frequent finding in the course of Case Report inflammatory bowel disease. They are non-neoplastic lesions resulting from a regenerative and healing process that leaves A 45-year-old male patient was admitted to our service in July inflamed colonic mucosa in polypoid configuration. Data about 2002 for acute rectal bleeding. All laboratory tests were their management is lacking. "Giant" pseudopolyps can be normal, except an increase of aminotransferases level (>10 N) mistaken for adenocarcinomas and, as they rarely regress with and a serological profile consistent with acute hepatitis B or a medical management alone, a surgical resection is often required. flare of chronic hepatitis B (HbsAg +, HbsAb –, HbeAg –, A case of giant pseudopolyposis treated non-surgically, in a patient HbeAb +, HbcAb-IgM +). The patient underwent lower with concomitant ulcerative colitis and chronic hepatitis B, is gastro-intestinal endoscopy and multiple biopsies were taken reported, representing a co-morbidity complicating an eventual from a bulky rectal mass lesion (Figure 1). Histological study conservative treatment. The clinical implementation of topical revealed alterations compatible with inflammatory bowel budesonide was originally tested, resulting in clinical, endoscopic disease (IBD) with no dysplasia (Figure 2). Because of the and histological remission. Budesonide seems a promising therapy atypical macroscopic features and the high suspicion of rectal for IBD, particularly when a comorbidity with viral hepatitis exist.
    [Show full text]
  • Practice Parameters for the Surgical Treatment of Ulcerative Colitis Howard Ross, M.D
    PRACTICE PARAMETERS Practice Parameters for the Surgical Treatment of Ulcerative Colitis Howard Ross, M.D. • Scott R. Steele, M.D. • Mika Varma, M.D. • Sharon Dykes, M.D. Robert Cima, M.D. • W. Donald Buie, M.D. • Janice Rafferty, M.D. Prepared by the Standards Practice Task Force of the American Society of Colon and Rectal Surgeons he American Society of Colon and Rectal Surgeons the most common surgical indication for UC. Whether is dedicated to assuring high-quality patient care it is secondary to an inability to control symptoms, poor Tby advancing the science, prevention, and manage- quality of life, risks/side effects of chronic medical therapy ment of disorders and diseases of the colon, rectum, and (especially long-term corticosteroids), noncompliance, or anus. The Standards Committee is composed of Society growth failure, patients may opt for surgery in the elective members who are chosen because they have demonstrat- or semielective setting.3 Complete removal of all the poten- ed expertise in the specialty of colon and rectal surgery. tial disease-bearing tissue is theoretically curative in UC. This Committee was created to lead international efforts Operative options include an abdominal colectomy or total in defining quality care for conditions related to the co- proctocolectomy with either a permanent end ileostomy or lon, rectum, and anus. This is accompanied by develop- surgical construction of a “new” rectum through an IPAA ing Clinical Practice Guidelines based on the best available that restores GI continuity.4,5 All these procedures may evidence. These guidelines are inclusive, and not prescrip- be performed by using open or minimally invasive tech- tive.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub
    US 2010O221245A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub. Date: Sep. 2, 2010 (54) TOPICAL SKIN CARE COMPOSITION Publication Classification (51) Int. Cl. (76) Inventor: Audrey Kunin, Mission Hills, KS A 6LX 39/395 (2006.01) (US) A6II 3L/235 (2006.01) A638/16 (2006.01) Correspondence Address: (52) U.S. Cl. ......................... 424/133.1: 514/533: 514/12 HUSCH BLACKWELL SANDERS LLP (57) ABSTRACT 4801 Main Street, Suite 1000 - KANSAS CITY, MO 64112 (US) The present invention is directed to a topical skin care com position. The composition has the unique ability to treat acne without drying out the user's skin. In particular, the compo (21) Appl. No.: 12/395,251 sition includes a base, an antibacterial agent, at least one anti-inflammatory agent, and at least one antioxidant. The (22) Filed: Feb. 27, 2009 antibacterial agent may be benzoyl peroxide. US 2010/0221 245 A1 Sep. 2, 2010 TOPCAL SKIN CARE COMPOSITION stay of acne treatment since the 1950s. Skin irritation is the most common side effect of benzoyl peroxide and other anti BACKGROUND OF THE INVENTION biotic usage. Some treatments can be severe and can leave the 0001. The present invention generally relates to composi user's skin excessively dry. Excessive use of some acne prod tions and methods for producing topical skin care. Acne Vul ucts may cause redness, dryness of the face, and can actually garis, or acne, is a common skin disease that is prevalent in lead to more acne. Therefore, it would be beneficial to provide teenagers and young adults.
    [Show full text]
  • The Comparison of the Effect Between Alginate-Based Raft-Forming Liquid and Alginate Liquid on Gastroesophageal Reflux Disease and Gastric Ulcer in Rats
    Online - 2455-3891 Vol 10, Issue 12, 2017 Print - 0974-2441 Research Article THE COMPARISON OF THE EFFECT BETWEEN ALGINATE-BASED RAFT-FORMING LIQUID AND ALGINATE LIQUID ON GASTROESOPHAGEAL REFLUX DISEASE AND GASTRIC ULCER IN RATS HAKIM BANGUN1*, ANAYANTI ARIANTO1, RIRIN ASTYA1, GONTAR A SIREGAR2 1Department of Pharmaceutical Technology, Faculty of Pharmacy, Nanomedicine Center, University of Sumatera Utara, Jl. Tri Dharma No. 5, Kampus USU, Medan, Indonesia. 2Department of Internal Medicine, Faculty of Medicine, University of Sumatera Utara, Jl Dr. T. Mansyur No. 5, Kampus USU, Medan, Indonesia. Email: [email protected] Received: 04 July 2017, Revised and Accepted: 16 August 2017 ABSTRACT Objective: The objective of the study was to compare the effect between alginate (Alg)-based raft-forming and Alg liquid on healing gastroesophageal reflux disease (GERD) and gastric ulcer in rats. Methods: Each of the 18 fasted rats was given 1 ml acidified pepsin. Then, rats were divided into three groups. Each group consisted of six rats. Group 1 (negative control) was orally given 1 ml distilled water, Group 2 was given 1 ml Alg-based raft-forming liquid, and Group 3 was given 1 ml Alg liquid. Then, the abdomen of rats was incised under anesthesia with ketamine, and then both their pylorus and the forestomach were ligated to form gastric reflux. After 4 hrs, all rats were killed with chloroform and their esophagus and stomach were examined macroscopically and microscopically (histopathology). Results: On macroscopic observation, all of the Group 1 rats (negative control) showed esophageal lesions and gastric lesions. Four rats of Group 2 (given Alg-based raft-forming) showed no esophageal lesion and two more rats showed a slight lesion, but all of the tested rats showed gastric lesions.
    [Show full text]
  • RAFT FORMING SYSTEM a REVIEW Bhavsar Dhaval Niranjanbhai*, Varde Neha Mahendrakumar, C
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Journal of Drug Delivery and Therapeutics (JDDT) Bhavsar et al Journal of Drug Delivery & Therapeutics; 2012, 2(5), 123-128 123 Available online at http://jddtonline.info REVIEW ARTICLE ADVANCES IN GRDDS: RAFT FORMING SYSTEM A REVIEW Bhavsar Dhaval Niranjanbhai*, Varde Neha Mahendrakumar, C. Sini Surendran, Shah Viral H, Upadhyay UM Dept. of pharmaceutics, Sigma Institute of Pharmacy, Bakrol, Vadodara(Gujarat), India *Corresponding Author’s Ph: +91-9725512814, Email id: [email protected] Received 06 June 2012; Review Completed 26 Aug 2012; Accepted 26 Aug 2012, Available online 15 Sep 2012 ABSTRACT: In recent years several advancements has been made in research and development of Gastro retentive drug delivery system to overcome the drawback of non-site specificity when drug administered orally. In order to understand various physiological difficulties to achieve gastric retention, we have summarized important factors controlling gastric retention time. We have reviewed various gastro retentive approaches designed and developed until now i.e. floating drug dosage systems (FDDS), swelling or expanding systems, mucoadhesive systems, high density system, Raft forming system, magnetic systems. Among these systems, the review summarizes the special focus on raft forming approach which comes under floating drug delivery system. Raft system incorporates alginate gels which have carbonate components react with gastric acid causes bubbles and this enables floating. Finally, Evaluation, advantages, disadvantages, future potential and marketed preparation of raft forming approach in gastro retentive drug delivery systems were covered. Key words-Advances in GRDDS, Raft forming system, alginic acid, gaviscon, INTRODUCTION: Conventional oral delivery is widely used in 4) Drugs with a narrow window of absorption E.g.
    [Show full text]
  • Glucose-Uptake Activity and Cytotoxicity of Diterpenes and Triterpenes Isolated from Lamiaceae Plant Species
    molecules Article Glucose-Uptake Activity and Cytotoxicity of Diterpenes and Triterpenes Isolated from Lamiaceae Plant Species Ninon G. E. R. Etsassala 1 , Kadidiatou O. Ndjoubi 2 , Thilly J. Mbira 2, Brendon Pearce 3 , Keenau Pearce 3, Emmanuel I. Iwuoha 4 , Ahmed A. Hussein 2 and Mongi Benjeddou 3,* 1 Department of Horticultural Sciences, Cape Peninsula University of Technology, Symphony Rd., Bellville 7535, South Africa; [email protected] 2 Chemistry Department, Cape Peninsula University of Technology, Symphony Rd., Bellville 7535, South Africa; [email protected] (K.O.N.); [email protected] (T.J.M.); [email protected] (A.A.H.) 3 Precision Medicine Laboratory, Department of Biotechnology, 2nd Floor, Life Science Building, University of the Western Cape, Cape Town 7530, South Africa; brendon.biff@gmail.com (B.P.); [email protected] (K.P.) 4 Chemistry Department, University of the Western Cape, Private Bag X17, Bellville 7535, South Africa; [email protected] * Correspondence: [email protected]; Tel.: +27-21-959-2080; Fax: +27-21-959-3505 Academic Editors: Patrícia Rijo, Vera Isca and Daniele Passarella Received: 17 July 2020; Accepted: 14 August 2020; Published: 10 September 2020 Abstract: The prevalence of diabetes mellitus (DM), considered one of the most common metabolic disorders, has dramatically increased and resulted in higher rates of morbidity and mortality around the world in the past decade. It is well known that insulin resistance in target tissues and a deficiency in insulin secretion from pancreatic β-cells are the main characteristics of type 2 diabetes. The aim of this study was the bio-evaluation of compounds isolated from three selected plant species: namely, Salvia africana-lutea, Leonotis ocymifolia, and Plectranthus madagascariensis, for their glucose-uptake ability.
    [Show full text]
  • Lymphoid Organs of Neonatal and Adult Mice Preferentially Produce Active Glucocorticoids from Metabolites, Not Precursors ⇑ Matthew D
    Brain, Behavior, and Immunity 57 (2016) 271–281 Contents lists available at ScienceDirect Brain, Behavior, and Immunity journal homepage: www.elsevier.com/locate/ybrbi Full-length Article Lymphoid organs of neonatal and adult mice preferentially produce active glucocorticoids from metabolites, not precursors ⇑ Matthew D. Taves a,b, , Adam W. Plumb c, Anastasia M. Korol a, Jessica Grace Van Der Gugten d, Daniel T. Holmes d, Ninan Abraham b,c,1, Kiran K. Soma a,b,e,1 a Department of Psychology, University of British Columbia, 2136 West Mall, Vancouver V6T 1Z4, Canada b Department of Zoology, University of British Columbia, 4200-6270 University Blvd, Vancouver V6T 1Z4, Canada c Department of Microbiology and Immunology, University of British Columbia, 1365-2350 Health Sciences Mall, Vancouver V6T 1Z3, Canada d Department of Laboratory Medicine, St Paul’s Hospital, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada e Djavad Mowafaghian Centre for Brain Health, University of British Columbia, 2215 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada article info abstract Article history: Glucocorticoids (GCs) are circulating adrenal steroid hormones that coordinate physiology, especially the Received 4 March 2016 counter-regulatory response to stressors. While systemic GCs are often considered immunosuppressive, Received in revised form 22 April 2016 GCs in the thymus play a critical role in antigen-specific immunity by ensuring the selection of competent Accepted 7 May 2016 T cells. Elevated thymus-specific GC levels are thought to occur by local synthesis, but the mechanism of Available online 7 May 2016 such tissue-specific GC production remains unknown. Here, we found metyrapone-blockable GC produc- tion in neonatal and adult bone marrow, spleen, and thymus of C57BL/6 mice.
    [Show full text]
  • HMSA Drug Formulary
    March 23, 2004 MEMORANDUM TO: Participating Pharmacies FROM: John T. Berthiaume, M.D. Medical Director, Pharmacy Management SUBJECT: Updated HMSA Drug Formulary Enclosed is the comprehensive updated formulary, effective April 1. This copy incorporates the changes listed in the Formulary Update sent to you in February. Please replace the current formulary sections in your pharmacy handbook with the enclosed version. If you have any questions, please call an HMSA Provider Teleservice Representative at 948- 6330 on Oahu or 1 (800) 790-4672 from the Neighbor Islands. PM04-010 HMSA DRUG FORMULARY 4/1/04 - Page 1 Code THERAPEUTIC CATEGORY LISTING 1 I. Anti-infectives A. Antibiotics 1. Penicillins - non-penicillinase resistant 2 I. Anti-infectives A. Antibiotics 2. Penicillins - penicillinase resistant 3 I. Anti-infectives A. Antibiotics 3. Cephalosporins 4 I. Anti-infectives A. Antibiotics 4. Fluoroquinolones 5 I. Anti-infectives A. Antibiotics 5. Tetracyclines 6 I. Anti-infectives A. Antibiotics 6. Macrolides 7 I. Anti-infectives A. Antibiotics 7. Vancomycin 8 I. Anti-infectives A. Antibiotics 8. Lincosamides 9 I. Anti-infectives A. Antibiotics 9. Aminoglycoside 10 I. Anti-infectives A. Antibiotics 10. Sulfonamides 11 I. Anti-Infectives A. Antibiotics 11. Vaginal preparations 12 I. Anti-infectives B. Antifungal agents 1. Oral 13 I. Anti-Infectives B. Antifungal agents 2. Vaginal preparations OTC considerations: clotrimazole (Gyne-Lotrimin 3, Mycelex-7), miconazole (Monistat 7), tioconazole (Vagistat-1), butoconazole (Femstat 3) 14 I. Anti-infectives C. Antimalarial 15 I. Anti-infectives D. Antituberculous 16 I. Anti-infectives E. Amebicides 17 I. Anti-infectives F. Antiviral agents 1. Nucleoside Reverse-transcriptase Inhibitors (NRTI) 18 I.
    [Show full text]
  • In Vivo Evaluation of Antidiarrhoeal Activity of the Leaves of Azima Tetracantha Linn
    Vol.5(8), pp. 140-144, December, 2013 DOI: 10.5897/IJNAM2013.0152 International Journal of Nutrition and ISSN 2141-2340 ©2013 Academic Journals http://www.academicjournals.org/IJNAM Metabolism Full Length Research Paper In vivo evaluation of antidiarrhoeal activity of the leaves of Azima tetracantha Linn V. Hazeena Begum*, M. Dhanalakshmi and P. Muthukumaran Department of Siddha Medicine, Faculty of Science, Tamil University, Vakaiyur, Thanjavur 613 010, Tamilnadu, India. Accepted 3 October, 2013 The aqueous crude extract of the leaves of Azima tetracantha was studied for its phytochemical constituents and antidiarrhoeal activity using castor oil-induced diarrhoea and castor oil-induced enteropooling in rats. The phytochemical studies of the aqueous extract revealed the presence of alkaloids, flavonoids, tannins and saponins. The extract showed significant (p < 0.001) protection against castor oil-induced diarrhoea and castor oil-induced enteropooling at (100 mg/kg). The presence of some of the phytochemicals in the root extract may be responsible for the observed effects, and also the basis for its use in traditional medicine as antidiarrhoeal drug. Key words: Azima tetracantha, enteropooling, anti-diarrhoeal. INTRODUCTION Diarrhoea is characterized by increased frequency of powerful diuretic given in rheumatism, dropsy, dyspepsia bowel movement, wet stool and abdominal pain and chronic diarrhoea and as a stimulant tonic after (Ezekwesili et al., 2004). It is a leading cause of confinement (Nadkarni, 1976). A. tetracantha as efficient malnutrition and death among children in the developing acute phase anti-inflammatory drug is traditionally used countries of the world today (Victoria et al., 2000). Many by Indian medical practitioners (Ismail et al., 1997).
    [Show full text]